The FDA-approved CDK4/6 inhibitor Abemaciclib is a potent agonist of the β-arrestin-biased atypical chemokine receptor ACKR3
Maurice C.M.L. Buzink, Joy Darcis, Desislava Nesheva, Max Meyrath, Shawn Jenjak, Nilanjana Banerjee, Manisankar Ganguly, Ashna Reyaz, Ramanuj Banerjee, Esther A. Leliveld, Yong-Jun Kwon, Jerome Paggetti, Sybrand Zielhuis, Dick Pluim, Alwin Huitema, , Rob Leurs
This paper identifies abemaciclib, an FDA-approved CDK4/6 inhibitor, as a potent agonist of ACKR3, an atypical chemokine receptor, revealing its ability to modulate chemokine availability and receptor activity.
bioRxiv · Nov 4, 2026 · PreprintMolecular Biology